| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f608437b78674d77bd371f635a364d56 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
1992-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2000-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81d29b14662ae60390dacfacb5f00cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_059110ecb387aea8606fe2a58fb8b1af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e91873900c9dac328a6f1ec6a950e0b5 |
| publicationDate |
2000-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0529031-B1 |
| titleOfInvention |
Improved inhibitors of thrombin |
| abstract |
This invention relates to coating invasive devies with novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of the formula: <IMAGE> wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted saturated ring structures; R2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R4 is any amino acid; R5 is any L-amino acid which comprises a guanidinium- or amino-containing side chain group; R6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: <IMAGE> wherein R1' is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R4' is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 9.5; and X, R2, R3, R5, R6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exosite associating domain (ABEAM) and a linker portion of between 18 ANGSTROM and 42 ANGSTROM in length which connects the Y to the ABEAM. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9988461-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9988463-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9518128-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9518129-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019030706-A1 |
| priorityDate |
1991-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |